A real world study assessing the efficacy of Fremanezumab in reductions of monthly migraine days and monthly headache days in patients with episodic/chronic migraine
Latest Information Update: 18 Aug 2022
At a glance
- Drugs Fremanezumab (Primary)
- Indications Migraine
- Focus Therapeutic Use
Most Recent Events
- 18 Aug 2022 New trial record
- 28 Jun 2022 Results of an analysis assessed the migraine- related healthcare resource utilization presented at the 8th Congress of the European Academy of Neurology
- 28 Jun 2022 Results presented at the 8th Congress of the European Academy of Neurology